Cedrin | CAS# 6040-62-6 | antihistamine

MedKoo Cat#: 412488 | Name: Cedrin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cedrin is an antihistamine that reduces the natural chemical histamine in the body

Chemical Structure

Cedrin

CAS#6040-62-6

Theoretical Analysis

MedKoo Cat#: 412488

Name: Cedrin

CAS#: 6040-62-6

Chemical Formula: C15H18O6

Exact Mass: 294.1103

Molecular Weight: 294.30

Elemental Analysis: C, 61.22; H, 6.17; O, 32.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cedrin

IUPAC/Chemical Name

Naphtho(1,2-b)furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-4,5-dihydroxy-9-methoxy-3,5a-dimethyl-

InChi Key

NMBLGAVLJLFABK-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H18O6/c1-6-8-10(17)13(18)15(2)5-4-7(16)11(20-3)9(15)12(8)21-14(6)19/h4-6,8,10,12-13,17-18H,1-3H3

SMILES Code

O=C1C(C)C(C(O)C(O)C2(C)C=CC(C(OC)=C23)=O)C3O1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 294.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhao Z, Dong Z, Ming J, Liu Y. Cedrin identified from Cedrus deodara (Roxb.) G. Don protects PC12 cells against neurotoxicity induced by Aβ1-42. Nat Prod Res. 2018 Jun;32(12):1455-1458. doi: 10.1080/14786419.2017.1346645. Epub 2017 Jun 29. PMID: 28658984. 2: Cédrin-Durnerin I, Isnard T, Mahdjoub S, Sonigo C, Seroka A, Comtet M, Herbemont C, Sifer C, Grynberg M. Serum progesterone concentration and live birth rate in frozen-thawed embryo transfers with hormonally prepared endometrium. Reprod Biomed Online. 2019 Mar;38(3):472-480. doi: 10.1016/j.rbmo.2018.11.026. Epub 2019 Jan 5. PMID: 30642638. 3: Cédrin-Durnerin I, Huques JN. Aménorrhée [Amenorrhoea]. Rev Prat. 2004 Mar 15;54(5):557-62. French. PMID: 15176516. 4: KREBS KG, RUBER HE. [The ingredients of the seed of Simaba cedron Planchon. Part 1. Cedrin]. Arzneimittelforschung. 1960 Jul;10:500-5. German. PMID: 14411865. 5: Agrawal PK, Agarwal SK, Rastogi RP, Osterdahal BG. Dihydroflavanonols from Cedrus deodara, A (13)C NMR study. Planta Med. 1981 Sep;43(1):82-5. doi: 10.1055/s-2007-971478. PMID: 17402014. 6: Cédrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Théron L, Wolf JP, Conord C, Clément P, Jayot S, Hugues JN. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2004 Sep;19(9):1979-84. doi: 10.1093/humrep/deh369. Epub 2004 Jun 10. PMID: 15192072. 7: Cédrin-Durnerin I, Guivarc'h-Levêque A, Hugues JN; Groupe d'Etude en Médecine et Endocrinologie de la Reproduction. Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertil Steril. 2012 Jun;97(6):1359-64.e1. doi: 10.1016/j.fertnstert.2012.02.028. Epub 2012 Mar 28. PMID: 22464760. 8: Cédrin-Durnerin I, Bstandig B, Galey J, Bry-Gauillard H, Massin N, Hugues JN. Beneficial effects of GnRH agonist administration prior to ovarian stimulation for patients with a short follicular phase. Reprod Biomed Online. 2003 Sep;7(2):179-84. doi: 10.1016/s1472-6483(10)61748-8. PMID: 14567886. 9: Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, Decanter C, Hugues JN. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007 Jan;22(1):109-16. doi: 10.1093/humrep/del340. Epub 2006 Aug 26. PMID: 16936304. 10: Cedrin-Durnerin I, Massin N, Galey-Fontaine J, Bry-Gauillard H, Roger M, Lahlou N, Hugues JN. Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment. Hum Reprod. 2006 Nov;21(11):2941-7. doi: 10.1093/humrep/del259. Epub 2006 Jul 27. PMID: 16877377.